Vertex Pharmaceuticals Unrecognized tax benefits, deferred tax liabilities, gross remained flat by 0.0% to $34.63M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 50.7%, from $22.98M to $34.63M. Over 2 years (FY 2023 to FY 2025), Unrecognized tax benefits, deferred tax liabilities, gross shows a downward trend with a -7.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher levels indicate a larger potential tax liability should the company's tax positions be challenged or disallowed by authorities.
The total gross amount of deferred tax liabilities that are directly linked to unrecognized tax benefits. This represent...
Standard tax footnote disclosure used to evaluate the scale of potential tax liabilities.
other_unrecognized_tax_benefits_deferred_tax_liabilities_gross| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $160.00M | $91.90M | $138.50M |
| YoY Change | — | -42.6% | +50.7% |